Abstract:Michael H Storandt, 1 Zhaohui Jin, 2 Amit Mahipal 3 1 Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2 Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA; 3 Department of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA Correspondence: Amit Mahipal, University Hospitals Seidman Cancer Center, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH, 44106, USA, Tel +1 216-844-3951, Email Advanced biliary tract cancers (BTCs) have historically been managed with chemotherapy but, in recent years, this treatment paradigm has begun to shift with the introduction of immune checkpoint inhibitors in addition to standard of care chemotherapy. The tumor microenvironment of BTC may be enriched with regulatory T lymphocytes and immune checkpoint expression in some patients. Durvalumab, an anti-programmed death ligand-1 (PD-L1) antibody, in combination with gemcitabine and cisplatin, has now received United States Food and Drug Administration approval for treatment of advanced BTC. Regulatory approval was based on the Phase III, randomized TOPAZ-1 trial that demonstrated survival benefit with addition of durvalumab to gemcitabine plus cisplatin compared to chemotherapy alone. The combination of chemotherapy and immunotherapy was well tolerated, and a subset of patients were able to achieve a durable response, with a 2-year overall survival rate of 23.6%. However, limitations remain in identifying which patients are most likely to benefit from immune checkpoint inhibition. Future study should aim to identify biomarkers predictive of substantial benefit, as well as the role of immune checkpoint inhibition in combination with targeted therapies and radiotherapy in the management of advanced BTC. Keywords: durvalumab, immunotherapy, cholangiocarcinoma, bile duct cancers Biliary tract cancers (BTCs), arising from the biliary epithelium, include intra- and extra-hepatic cholangiocarcinoma (CCA), gallbladder carcinoma (GC), and ampullary carcinoma (AC). BTC has an incidence of 2.32 cases per 100,000 in the United States (US) and, globally, the highest incidence is found in Asia and South America. 1 In the US, the most common subtype is intrahepatic CCA, with an estimated incidence of approximately 1.5 cases per 100,000, followed by GC, extrahepatic CCA, and lastly, AC. 2 The incidence of BTCs is projected to increase in the coming years, with the largest contribution by intrahepatic CCA. 3,4 Historically, treatment of advanced BTC consisted of gemcitabine plus cisplatin based on ABC-02, which randomized patients with advanced or metastatic BTC to gemcitabine with or without cisplatin and demonstrated an improvement in median overall survival (mOS) with the combination regimen compared to single agent gemcitabine [11.7 vs 8.1 months, hazard ratio (HR) = 0.64, 95% confidence interval (CI) = 0.52–0.80, p <0.001]. 5 Following this trial, subsequent studies failed to demonstrate the superiority of alternative regimens. SWOG 1815 failed to show a survival benefit with the addition of nab-paclitaxel to gemcitabine plus cisplatin. 6 PRODIGE 38 AMEBICA, which randomized patients to FOLFIRINOX or gemcitabine plus cisplatin, failed to meet its primary endpoint of improved 6-month progression free survival (PFS). 7 As such, gemcitabine plus cisplatin remained the standard of care for management of BTCs in the first line setting for over 10 years. Unfortunately, the prognosis for patients with advanced BTC remained poor, prompting the need for better options. More recently, the role of immunotherapy in combination with standard chemotherapy has been evaluated in advanced BTC, including immune checkpoint inhibitors such as durvalumab and pembrolizumab. This is in line with recent changes in management of hepatocellular carcinoma, with first line options now including atezolizumab plus bevacizumab following the IMbrave150 trial, and the combination of tremelimumab plus durvalumab following the HIMALAYA trial. 8,9 As of September 2022, durvalumab in addition to chemotherapy has received US Food and Drug Administration (FDA) approval for treatment of advanced or metastatic BTC in the first-line setting. This was followed by FDA approval for pembrolizumab plus chemotherapy in 2024. This review will aim to discuss the role of durvalumab in the treatment of advanced BTC and summarize the current evidence to date. Before discussing the role of immunotherapy in BTC, it is important to understand the tumor microenvironment (TME) and how it may facilitate a response to immune checkpoint inhibition. The TME of BTC contains different cell populations, including regulatory T cells, cancer associated fi -Abstract Truncated-

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

Lenvatinib Plus PD-1 Inhibitors As First-Line Treatment in Patients with Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).

Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population

Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date

Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Immunotherapy for the treatment of biliary tract cancer: an evolving landscape

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer

Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naïve advanced biliary tract cancer.

Evaluation of Overall Survival by Restricted Mean Survival Time of Advanced Biliary Tract Cancer treated with Immunotherapy: A Systematic Review and Meta-Analysis

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives

AB052. P-20. Phase 2, Open-Label Study of Second-Line M7824 Treatment in Patients with Locally Advanced or Metastatic Biliary Tract Cancer

Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.

Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.